Doxazosin controlled release - Shiner PharmAlternative Names: Haxasin
Latest Information Update: 11 Feb 2016
At a glance
- Originator Shiner Pharm Corp
- Class Antihypertensives; Quinazolines; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Benign prostatic hyperplasia; Hypertension